Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:
9 Examples of Collaborations Relevant to Cancer
9 Examples of Collaborations Relevant to Cancer
Pages 69-72
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 69... ...
"Rather than just us focusing on our own inhibitor, we talked to Novartis. Similarly Genentech and Roche are collaborating on the preclinical development of a combination treatment that targets both P13K and MEK, and AstraZeneca is collaborating with Merck in the preclinical development of a combination that targets PI3K and ATK," Dr.
|
From page 70... ...
Herbst said. The PI3K team funded by Stand Up To Cancer has invested $500,000 to purchase 50–100 gram quantities of 10 investigational drugs that recently entered Phase II clinical trials and that were of interest to them for combination therapies.
|
From page 71... ...
Cantley pointed out. But he added that in general, it takes about a year to acquire a material transfer agreement with a company in order to use their investigational agent to test in their animal models, and most agree ments stipulate the agent cannot be combined with any other drug.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.